Disclosure. Instead of JNC 8. Proposed Reasons for Delays. Outline 6/10/2013. Member of JNC 8 panel No other disclosures. Daniel T.
|
|
- Brianne Reynolds
- 5 years ago
- Views:
Transcription
1 An Update on The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8): The Evidence-Based Process Disclosure Member of JNC 8 panel No other disclosures Daniel T. Lackland Instead of JNC 8 Proposed Reasons for Delays JNC Late JNC Wait JNC 9 JNC Ache Panel is lazy Panel does not know what they doing Too much wine at meetings Panel members do not like each other The epidemiologist!!!! Outline Hypertension Risks and Previous JNC Reports Evidence-based approach for JNC 8 Lifestyle Adherence Summary 3-year mortality risk ratios for elevated blood pressure controlling for age, SES, smoking, cholesterol and diabetes: Charleston and Evans County Heart Studies White Males 14/9 1.6 (1.,.) White Females 1.4 (1.1,.) Black Males.1 (1.3, 3.1) Black Females. (1.,.8) 16/ (1.3,.). (1.,.6).4 (1.5, 3.5).4 (1.6, 3.) Lackland Clinical and Experimental Hypertension,
2 IHD Mortality (absolute risk and 95% CI) Risk of increased systolic blood pressure consistent through all age groups Ischemic Heart Disease Mortality One Million Adults, 61 Prospective Studies Usual Systolic BP (mm Hg) IHD = ischemic heart disease. Lewington S et al. Lancet. ;36: Age at Risk (y) Stroke 3 Mortality (absolute 16 risk and 8 95% CI) 4 1 Stroke Mortality Usual Systolic BP (mm Hg) Age at Risk (y) CV mortality risk CV Mortality* Risk Doubles with Each /1 mm Hg BP Increment* Age 4-7 years Ref: Lancet. ; 6: JNC 7 Express. JAMA. 3;89: /75 135/85 155/95 175/15 SBP/DBP (mm Hg) Evolution of Treatment Recommendations JNC I JNC II JNC III JNC IV JNC V JNC VI JNC * # Stepped care diuretic to methyldopa reserpine, or propranolol Stepped care diuretic to adrenergicinhibiting agents Thiazide diuretics or BBs Thiazide diuretics, BBs, ACE-Is, or CCBs Thiazide diuretics or BBs Thiazide diuretics or BBs; for renoand cardioprotection ARBs recommended in patients intolerant of ACE-Is Thiazide diuretics, ARBs, ACE-Is, BBs, or CCBs; combination therapy for Stage SBP (mm Hg) Evolution of SBP Classification No recommendations for SBP in JNC I or JNC II ISH Borderline Borderline Normal Stage 3 Stage Stage 1 Stage 1 Highnormal Normal Optimal Highnormal Normal Optimal JNC I JNC II JNC III JNC IV JNC V JNC VI ISH Stage 4 Stage 3 Stage Stage Stage 1 Prehypertension Normal JNC 7 BB = β-blocker; ACE-I = angiotensin-converting enzyme inhibitor; CCB = calcium-channel blocker; ARB = angiotensin-receptor blocker. *JNC I. JAMA. 1977;37:55-61; JNC II. Arch Intern Med. 198;14:18-185; JNC III. Arch Intern Med. 1984;144: ; JNC IV. Arch Intern Med. 1988;148:13-138; JNC V. Arch Intern Med. 1993;153: ; # JNC VI. Arch Intern Med. 1997;157: ; **Chobanian AV et al. JAMA. 3;89: SBP = systolic blood pressure; ISH = isolated systolic hypertension. JNC I. JAMA. 1977;37:55-61; JNC II. Arch Intern Med. 198;14:18-185; JNC III. Arch Intern Med. 1984;144: ; JNC IV. Arch Intern Med. 1988;148:13-138; JNC V. Arch Intern Med. 1993;153: ; JNC VI. Arch Intern Med. 1997;157: ; Chobanian AV et al. JAMA. 3;89: After Intervention Population-Based Strategy SBP Distributions Reduction in BP Before Intervention Mean Systolic Blood Pressure by Time Period and JNC Report NHANES I-IV Years JNC Reports Population Average Systolic Blood Pressure mm hg mm hg JNC I (1977)/JNC II (198) 16 mm hg JNC III (1984) JNC IV (1988) 119 mm hg JNC V (1993) 11 mm hg JAMA. 3;89:56-57 Reduction in SBP mmhg 3 5 % Reduction in Mortality Stroke CHD Total JNC VI (1997) (JNC 7) 13 mm hg mm hg Lackland. CURRENT OPINION IN NEUROLOGY 6:8-1, 13.
3 Percent, % Percent Percent of Population 6/1/13 Percentage of Patients with Hypertension at Goal Prevalence Awareness Treated Controlled Controlled/treated Patients with diabetes (goal <13/8) 5%* 35%** Chronic kidney disease (goal <13/8) 18% 3% Overall (goal <14/9) 3% 51% Patients 6 yrs old (ISH) (goal <14/9) 7% 44% 6 Stroke (goal <14/9) 6% 33% JAMA 1;33:43 5. Peripheral artery disease (goal <14/9) 9% 39% Heart failure (goal <14/9) 46% 55% Coronary heart disease (goal <14/9) 49% 58% * Control, all hypertensives ** Control, all treated hypertensives Hajjar I, Kotchen TA. (3), JAMA 9():199-6 Wong, et al. submitted for publication Hypertension Prevalence, Awareness, Treatment and Control by Region P<.1 Hypertension NS Awareness NS Treatment P <.1 Control Southeast Non-Southeast Hypertension Prevalence by Age and Region P<.1 P<.1 < Age NS Southeast Non-Southeast Odds Ratio for Southeast residence adjusting for age, race and gender SPS3 Primary Outcome: Ischemic & Hemorrhagic Stroke Condition Odds Ratio 95% Confidence Interval Hypertension Prevalence ,1.9 Awareness , Treatment , 1.58 Control , 1.18 Resistant Hypertension , Higher Target Group= 15(.8%/yr) Lower Target Group= 15 (.3 %/yr) HR.81 (.64, 1.3) p value.8 Lower Higher International Stroke Conference, 13 3
4 SPS3 Ischemic Stroke & Intracerebral Hemorrhage Ischemic Stroke Higher Target Group= 131(.4%/yr) Lower Target Group= 11 (. %/yr) HR:.85 (.66, 1.1). p value:.1 Intracerebral Hemorrhage Higher Target Group= 16 (.9%/yr) Lower Target Group= 6 (.11 %/yr) HR.84 (.66, 1.9) p value.19 HR.37 (.15,.95) p value.3 SPS3 Conclusions Achieving a lower systolic blood pressure target was feasible, safe and well tolerated. Targeting a systolic blood pressure < 13 mm Hg is likely to reduce recurrent stroke by about % (caveat: p=.8). The lower blood pressure target significantly reduced intracerebral hemorrhage by two thirds. Previous trials of blood pressure lowering after stroke are consistent with our results. International Stroke Conference 13 International Stroke Conference 13 Outline Hypertension Risks and Previous JNC Reports Evidence-based approach for JNC 8 Lifestyle Adherence Summary Scientific Evidence Underlying ACC/AHA Guidelines (JAMA, 9; 31: ) AHA Level of Evidence A in Current Guidelines* AF Heart failure PAD STEMI Perioperative Secondary prevention Stable angina SV arrhythmias UA/NSTEMI Valvular disease VA/SCD PCI CABG Pacemaker Radionuclide Imaging.3% 6.4% 6.1% 11.7% 9.7% 11.% 15.3% 13.5% 1.% 19.%.9% 3.6% 6.4% *in guidelines with level of evidence 4.9% 4.8%.% 1.%.% 3.% Scientific Evidence Underlying ACC/AHA Guidelines Of 16 current GL with Level Of Evidence recommendations 11% (314/711) are A 48% (146/711) are C Only 9% (45/711) are Class I and Level of Evidence A JNC 8 Evidence-based approach Determine sufficient evidence Grade the evidence (JAMA, 9; 31: ) 4
5 Adult CVD Guidelines: NHLBI Approach Advice to NHLBI from advisory groups: Update risk factor guidelines (hypertension, cholesterol, obesity) Develop an integrated guideline Use an evidence-based approach including systematic reviews The NHLBI guideline development process Was established to assure rigor and to minimize bias Methods being used to meet many of the new IOM standards Two recent IOM reports set new standards Finding What Works in Health Care - standards for systematic reviews Clinical Practice Guidelines We Can Trust - standards for developing trustworthy CPGs How the Process Has Evolved Strictly evidence-based Focus only on randomized controlled trials assessing important health outcomes (no use of intermediate/surrogate measures) Every included study is rated for quality by two independent reviewers using standardized tools Evidence statements graded for quality using pre-specified criteria Separate grading for recommendations Independent methodology team to ensure objectivity of the review Initial set of recommendations focused on 3 key questions Expertise Represented Hypertension, primary care, cardiology, nephrology, clinical trials, research methodology, evidence-based medicine, epidemiology, guideline development and implementation, nutrition/lifestyle, nursing, pharmacology, systems of care, and informatics Question selection process Panel chairs and NHLBI staff developed draft questions based on expertise, literature, and colleague discussions Panel reviewed, revised, added/deleted questions resulting in 3 questions 5 questions were identified with highest priority The 5 questions were prioritized by the panel Rationale for the Questions Interest in assessing the evidence to support 14/9 mm Hg as a treatment threshold or goal Should the treatment threshold/goal be lower in populations with diabetes, chronic kidney disease, coronary artery disease, stroke, and other co-morbidities or characteristics? Should the treatment threshold/goal be different in older adults? Use of different treatment thresholds and goals is confusing Is there evidence that treatment to lower BP with a particular drug or drug class improves outcomes compared to another? NHLBI CVD Prevention Guidelines Expert Panels and Work Groups BP Panel Evidence Review on BP Tx 3 CQs Lifestyle WG Evidence Review on Diet & Physical Activity 3 CQs (1 SR) Cholesterol Panel Evidence Review on Cholesterol Tx 3 CQs Risk Assessment WG Evidence Review & Risk Prediction Model CQs+model (1SR) Obesity Panel Evidence Review on Obesity 5 CQs ( SRs) Five Draft Reports released for public comment, one at a time Implemetation WG Implementability Guidance (GLIA) Implementation Science Review 5
6 NHLBI Evidence Quality Grading and Recommendation Strength Evidence Quality High Well-designed and conducted RCTs Moderate RCTs with minor limitations Well-conducted observational studies Low RCTs with major limitations Observational studies with major limitations Recommendation Strength A- Strong B- Moderate C- Weak D- Against E- Expert Opinion N- No Recommendation Question 1 Among adults with hypertension, does initiating antihypertensive pharmacological therapy at specific BP thresholds improve health outcomes? -When to initiate drug treatment? Question Question 3 Among adults, does treatment with antihypertensive pharmacological therapy to a specified BP goal lead to improvements in health outcomes? -How low should you go? In adults with hypertension, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes? -How do you get there? Inclusion/Exclusion Criteria Populations Included Randomized Controlled Trials Less bias and standard for efficacy and effectiveness 1966-present time period Minimum 1-year follow-up Studies with sample size less than 1 excluded Institutes of Medicine 11. Finding What Works in Health Care: Standards for Systematic Reviews. Washington DC. National Academies Press. Adults 18 years of age and older Prespecified subgroups including: Diabetes Chronic kidney disease Proteinuria Coronary artery disease Peripheral artery disease Previous stroke Heart failure Older Adults Men and women Racial and ethnic groups Smoking 6
7 Outcomes Overall mortality, CVD-related mortality, CKD-related mortality, myocardial infarction, heart failure, hospitalization for heart failure, stroke Coronary revascularization (includes coronary artery bypass surgery, coronary angioplasty and coronary stent placement), peripheral revascularization (includes carotid, renal, and lower extremity revascularization) End stage renal disease (i.e., kidney failure resulting in dialysis or transplant), doubling of creatinine, halving of egfr Literature Review and Assessment Process Systematic search of literature for the CQ Citations found using inclusion/exclusion criteria Papers screened and reviewed for inclusion Result: unbiased list of studies based on a priori criteria Quality of each included study rates Good, fair, poor NHLBI study rating instruments Controlled intervention studies Cohort and cross-sectional studies Case-control studies Systematic reviews and meta-analyses NHLBI Assessment Tool reviews Quality rating Reasons for poor Randomization description, blinding, etc Data Abstraction and Evidence Tables Information from individual studies (key data, sample size, intervention, results, comparisons Evidence by critical question (tables and text relevant to critical questions Graded evidence statements (multiple evidence statements for each critical question Graded recommendations (multiple evidence statements could result in one recommendation) Question 1: Among adults with hypertension, does initiating antihypertensive pharmacological therapy at specific BP thresholds improve health outcomes? Question : Among the adults, does treatment with antihypertensive pharmacological therapy to a specified BP goal lead to improvements in health outcome? Articles Screened= 1496 Articles Screened= 1978 Included= 44 Excluded= 145 (Did not meet prespecified inclusion criteria) Included= 9 Excluded= 1886 (Did not meet prespecified inclusion criteria) Good=8 Fair= 18 Poor= 18 Good=17 Fair= 39 Poor= 36 Total Abstracted= 6 Total Abstracted= 56 7
8 Question 3: In adults with hypertension, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes? Included= 11 Good=15 Fair= 51 Total Abstracted= 66 Articles Screened= 66 Excluded= 561 (Did not meet prespecified inclusion criteria) Poor= 35 Adult CV Guideline Report Content Methods description Critical questions With study eligibility criteria and rationale Summary of evidence for each CQ Summary tables and text (e.g. 4 studies, 1 RCTs ) Graded evidence statements (ES) Rationale for ES based on specific studies or previous systematic reviews Graded High, Medium, Low Graded recommendations Rationale for the recommendation based on the evidence Graded A, B, C, D, E, or N Reference citations Conclusion The new NHLBI-sponsored adult CV guideline reports Are strictly evidence based Will not look like the previous guidelines Will have more depth and rigor; will have less breadth Will use evidence based strategies for implementation New reports vs Previous reports The new guideline reports will not look like the previous guidelines! Recommendations are based on systematic reviews of RCTs Restricted to a few critical questions More depth, less breadth (More rigor, less comprehensive) The new guideline reports will look more similar to each other than in the past Previous reports used different methods and structure New reports are using the same methods and structure Where are we? Evidence statements and recommendations Draft report Review of the draft report by: Other federal agencies (CDC, CMS, AHRQ, HRSA, VA, etc.) Invited organizations and individuals Public Revisions based on comments received - current Final report Outline Hypertension Risks and Previous JNC Reports Evidence-based approach for JNC 8 Lifestyle Adherence Summary 8
9 Change in Blood Pressure (mm Hg) Change in Weight (kg) 6/1/13 JNC 7: Management of Hypertension by BP Level JAMA. Classification 3;89: Initial Drug Therapy BP Classification Lifestyle Modification Normal < 1/8 mm Hg Encourage Without Compelling Indication With Compelling Indica DASH Diet Benefit of Lifestyle Modifications in Hypertension Management Bp Effect 8-14 mmhg Pre-hypertension 1-139/8-89 mm Hg Yes No drug indicated Drug(s) for the compe indications Weight Loss 1Kg- 5- mmhg Stage 1 hypertension /9-99 mm Hg Yes Drug Therapy Drug Therapy Low Sodium Diet Reduce Alcohol Intake -8 mmhg -4 mmhg ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin-receptor blocker; BB = β-blocker; CCB = calcium-channel blocker. Stage Chobanian AV hypertension et al. JAMA. 3;89: /1 mm Hg Yes Drug Therapy Drug Therapy Regular Exercise 4-9 mmhg Dietary Approaches to Stop Hypertension The Dash Diet DASH Diet Fruit Vegetables Low Fat Foods 8 Weeks of DASH Diet Systolic 11.6 mmhg Diastolic -5.3 mmhg African Americans 8 Weeks DASH Diet Systolic -13. mmhg Diastolic mmhg Dietary Recommendations Hypertensive patients and normotensive individuals at increased risk of developing hypertension consume a diet that emphasizes fruits, vegetables and low-fat dairy products, dietary and soluble fiber, whole grains and protein from plant sources and that is reduced in saturated fat and cholesterol (Dietary Approaches to Stop Hypertension [DASH] diet) (Grade B). DASH Diet Benefit of Lifestyle Modifications in Hypertension Management Weight Loss Low Sodium Diet Reduce Alcohol Intake Regular Exercise Bp Effect 8-14 mmhg 1Kg- 5- mmhg -8 mmhg -4 mmhg 4-9 mmhg Relationship Between Change in Weight and Blood Pressure: Trials of Hypertension Prevention II Diastolic Stevens et al. Ann Intern Med 1;134:1. Systolic Quintile of Weight Change
10 Weight Reduction Benefit of Lifestyle Modifications in Hypertension Management Height, weight, and waist circumference should be measured and body mass index calculated for all adults (Grade D). Maintenance of a healthy body weight (body mass index 18.5 to 4.9 kg/m² and waist circumference less than 1 cm for men and less than 88 cm for women) is recommended for non-hypertensive individuals to prevent hypertension (Grade C) and for hypertensive patients to reduce blood pressure (Grade B). All overweight and obese hypertensive individuals should be advised to lose weight (Grade B). Weight loss strategies should employ a multidisciplinary approach that includes dietary education, increased physical activity and behavioral intervention (Grade B). DASH Diet Weight Loss Low Sodium Diet Reduce Alcohol Intake Regular Exercise Bp Effect 8-14 mmhg 1Kg- 5- mmhg -8 mmhg -4 mmhg 4-9 mmhg Sodium Facts Sodium increases the risk of heart attack and stroke in all people even those without high blood pressure. Cutting out just one gram of sodium a day, the amount found in a ½ teaspoon of salt, can decrease the risk of a heart attack or stroke by 5 percent. Most Salt Comes from Processed and Restaurant Foods Processed and restaurant foods 77% Naturally occurring 1% While eating 6% Home cooking 5% Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 7;334;885; April,7. Source: Mattes, RD. Journal of American College Nutrition, 1991, 1: Most Salt Comes from Processed and Restaurant Foods Most Salt Comes from Processed and Restaurant Foods How much sodium is in a Chicken Cesar Salad at the Costco Food Court? A. 68mg B. 75 mg C. 113 mg D. 6 mg How much sodium is an order of PF Chang s, double pan fried noodles with pork? A. 15 mg B. 79 mg C. 7 mg D. 43 mg 1
11 Goal: % Reduction in Sodium Intake in 5 Years Decrease sodium content in foods by 5% over 5 years Decrease population sodium intake by ~ % over 5 years /3 LB** Double Bacon Cheese Thickburger Serving size (grams) = 46 Calories = 13 Sodium = 11 mg Reductions will vary among food categories Salt Intake Benefit of Lifestyle Modifications in Hypertension Management For prevention and treatment of hypertension, a dietary sodium intake of 15 mg (65 mmol) per day is recommended for adults age 5 years or less; 13 mg (57 mmol) per day if age 51 to 7 years; and 1 mg (5 mmol) per day if age greater than 7 years (Grade B). DASH Diet Weight Loss Low Sodium Diet Reduce Alcohol Intake Regular Exercise Bp Effect 8-14 mmhg 1Kg- 5- mmhg -8 mmhg -4 mmhg 4-9 mmhg Energy Content of Alcoholic Beverages Alcohol contains 7 kcal/g Beer 1 oz 16 calories Wine 5 oz 1 calories Margarita 8 oz 7 calories Gin and Tonic 8 oz (contains 1.7 oz gin) 19 calories 1 shot of liquor oz 18 calories Alcohol Consumption Healthy adults should limit alcohol consumption to two drinks or less per day, and consumption should not exceed 14 standard drinks per week for men and nine standard drinks per week for women (Grade B). one standard drink is considered 13.6 g or 17. ml of ethanol, or approximately 44 ml [1.5 oz] of 8 proof [4%] spirits, 355 ml [1 oz] of 5% beer or 148 ml [5 oz] of 1% wine.) 11
12 Weight Change (kg) Energy Expenditure (kcal/h) Activity (min/wk) 1 6/1/13 DASH Diet Benefit of Lifestyle Modifications in Hypertension Management Weight Loss Low Sodium Diet Reduce Alcohol Intake Regular Exercise Bp Effect 8-14 mmhg 1Kg- 5- mmhg -8 mmhg -4 mmhg 4-9 mmhg Energy Expenditure of Physical Activity All out competitive sports Running 1 mph Running 6 mph Climbing stairs Sexual intercourse Gardening Walking 4 mph Bicycling Walking mph Chewing gum (11 kcal/h) Alpers. Undergraduate Teaching Project. Nutrition: energy and protein. American Gastroenterological Association, Levine J, Baukol P, Ioannis P. The energy expended in chewing gum. N Engl J Med 1999;341:1. Effect of Low-Activity (1 kcal/wk) and High-Activity (5 kcal/wk) on Body Weight Jeffery et al. Am J Clin Nutr 3;78: Behavior therapy + Low activity P <.5 Behavior therapy + High activity Months Effect of Long vs Short Bouts of Exercise on Total Amount of Activity and Weight Loss Long Bouts P=.8 Short Bouts Long bout = one 4-min session. Short bout = four 1-min sessions. Jakicic et al. J Obes Relat Metab Disord 1995;19:893. Long Bouts P=.7 Short Bouts Weight Loss (kg) Physical Exercise For nonhypertensive individuals to prevent hypertension or for hypertensive patients to reduce their blood pressure: 3 to 6 minutes of moderate intensity dynamic exercise (such as walking, jogging, cycling or swimming) four to seven days per week in addition to the routine activities of daily living (Grade D). Higher intensities of exercise are no more effective (Grade D). For non-hypertensive or stage 1 hypertensive individuals, the use of resistance or weight training exercise (such as free weight lifting, fixed-weight lifting, or handgrip exercise) does not adversely influence BP (Grade D). Outline Hypertension Risks and Previous JNC Reports Evidence-based approach for JNC 8 Lifestyle Adherence Summary 1
13 Drugs don t work in patients who don t take them -- C. Everett Koop, MD, Former US Surgeon General What percent of prescription medications are actually taken as directed? 9% 75% 5% 5% Medication Use Continuum How Can Health Coaches Support Medication Adherence? The key to effective BP control appears to have more to do with patient and physician information exchange (or lack thereof) than with biology or drug failure. Eric D. Peterson, MD, MPH, Editorial: Is information the answer to hypertension control?, Arch Int Med. 4;168(3), RE: Ho PM, et al, Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med. 8;168(3):71-76 (KP Colorado) Outline Hypertension Risks and Previous JNC Reports Evidence-based approach for JNC 8 Lifestyle Adherence Summary Summary The hypertension control efforts have been effective JNC 8 will be evidence based and should also have an effect on control and lower disease outcomes Public health and lifestyle including sodium restriction provide an essential component of high blood pressure control Patient adherence is an important component of BP control 13
Status Report on the NHLBI-Sponsored CVD Prevention Guidelines
Status Report on the NHLBI-Sponsored CVD Prevention Guidelines HIGH BLOOD PRESSURE Paul A. James, M.D. Roy J. and Lucille A. Carver College of Medicine The University of Iowa Iowa City IA NHLBI Adult CVD
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationDisclosure of Relationships
JNC-8: Process, Critical Questions and Future Reports Barry L. Carter, Pharm.D., FCCP, FAHA, FASH The Patrick E. Keefe Professor in Pharmacy Department of Pharmacy Practice and Science College of Pharmacy
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationEvolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)
Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH) Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More information2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST
CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationObjective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel
Implementation: Joint National Committee on High Blood Pressure JNC 8 Joel Handler, MD Kaiser Permanente Care Management Institute Hypertension Lead Southern California Permanente Group Objective & Outline
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationRenal Disease through the Ages: From Childbearing years to Old Age. Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician.
Renal Disease through the Ages: From Childbearing years to Old Age Dr Elizabeth Jarvis, Renal Physician, General Physician, Obstetric Physician. Learning Outcomes: Understand the presentation of renal
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationA Needs Assessment of Hypertension in Georgia
A Needs Assessment of Hypertension in Georgia Faye Lopez Mercer University School of Medicine Marylen Rimando Mercer University School of Medicine Harshali Khapekar Mercer University School of Medicine
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More information7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)
University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationNUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N
NUTRITION IN THE AGE OF EVIDENCE D A N A H. M A N N I N G P H A R M. D., R. D., L D N OBJECTIVES List controversial points from the current Dietary Guidelines for Americans (DGA). Recognize the policy
More informationABSTRACT. Special Communication February 5, 2014
Page 1 of 20 Special Communication February 5, 2014 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationHypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
More informationMesures non médicamenteuses pour prévenir et traiter une hypertension artérielle. JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège
Mesures non médicamenteuses pour prévenir et traiter une hypertension artérielle JM Krzesinski Service de Néphrologie- Hypertension ULg-CHU Liège Disclosure No competing interest to declare about this
More informationSupplementary Online Content
Supplementary Online Content James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed to the Eighth Joint National
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationBROUGHT TO YOU BY. Blood Pressure
BROUGHT TO YOU BY Blood Pressure High blood pressure usually has no warning signs or symptoms, so many people don't realize they have it. According to the Center of Disease Control, CDC, about 75 million
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationManaging Hypertension in 2018
MANAGING HYPERTENSION IN 2018 How Do We Work With Conflicting Data and Conflicting Guidelines? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More information2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines
Hypertension: 214 Highlights of Hypertension Guidelines: Making the Most of Limited Evidence Michael A, Weber, MD Editor-in-Chief, The Journal of Clinical Hypertension, Professor of Medicine, Division
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationmajor public health burden
HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing
More informationAn Epidemiological Overview
An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationWhat is hypertension?
HYPERTENSION What is hypertension? Abnormally elevated arterial blood pressure that is usually indicated by an adult systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More information10/21/2014. Disclosures. Introduction. Reasons for the Decline in Stroke Mortality: Implications for Hypertension and Risk Factor Management
Reasons for the Decline in Stroke Mortality: Implications for Hypertension and Risk Factor Management Daniel T Lackland Disclosures Member of NHLBI Risk Assessment Workgroup Member of 2014 Hypertension
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationUnderstanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?
Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management? Slides presented during CDMC in Almaty, Kazakhstan on Saturday April 12,
More information4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise **
Supplementary Table 1. Search strategy (up to January 10 th 2015). MEDLINE Result: 253 studies 1. clinical trial ** OR controlled trial ** OR randomized controlled trial * OR randomised controlled trial
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationOsama Sanad (MD) Prof. of Cardiology Benha University 2016
Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned
More informationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 67, NO. 5, 2016 ª 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 0735-1097/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jacc.2015.10.037
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationHealth Score SM Member Guide
Health Score SM Member Guide Health Score Your Health Score is a unique, scientifically based assessment of seven critical health indicators gathered during your health screening. This number is where
More information